Researchers at Moffitt Cancer Center say identifying and selecting participants for phase II cancer clinical trials from a centralized warehouse of patient-donated biological data expedites participant accrual, reduces trial size, saves money, and may speed test drugs through the drug development pipeline. Their study, which analyzed datasets from recent clinical trials conducted at Moffitt, was published online recently in Statistical Methods in Medical Research...
More...
More...